Disease Overview：Helicobacter pylori infection（H. pylori infection）
Helicobacter pylori infection is a chronic bacterial colonization of the gastric mucosa, strongly associated with peptic ulcer disease, chronic gastritis, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and increased risk of gastric adenocarcinoma. H. pylori survives in the acidic gastric environment by producing urease, which neutralizes stomach acid locally. Diagnosis relies on non-invasive methods—including urea breath test, stool antigen assay, and serology—or invasive approaches such as rapid urease testing and histopathological examination of gastric biopsies during endoscopy. First-line eradication therapy typically involves a 10–14-day quadruple regimen: proton pump inhibitor (PPI), bismuth subsalicylate, and two antibiotics (e.g., tetracycline and metronidazole), tailored according to regional antibiotic resistance patterns. Treatment success hinges on adherence, accurate diagnosis, and susceptibility-guided regimens—especially given rising clarithromycin and levofloxacin resistance globally.
China offers distinct advantages for international patients seeking H. pylori management. Leading tertiary hospitals—many affiliated with top-tier medical universities—employ gastroenterologists with extensive experience in refractory and recurrent infections, supported by advanced endoscopic platforms (e.g., high-definition magnification endoscopy, real-time narrow-band imaging) and on-site molecular microbiology labs enabling rapid antimicrobial susceptibility testing. Clinical outcomes reflect this expertise: published studies from centers like Peking Union Medical College Hospital and Zhongshan Hospital report >92% first-line eradication rates using culture-guided regimens. Crucially, comprehensive care—including pre-treatment assessment, personalized therapy, post-eradication confirmation, and long-term surveillance—is delivered at approximately 40–60% lower cost than comparable services in the US, UK, or Germany, without compromising clinical rigor or safety standards.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: coordinating appointments with certified specialists, arranging accredited hospital admissions, providing transparent, all-inclusive pricing (covering diagnostics, treatment, follow-up, and interpreter support), and offering end-to-end assistance—from visa guidance and accommodation to post-discharge telehealth consultations.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: *Helicobacter pylori* Infection (Gastroenterology)
Non-Surgical/Medication-Based Therapy
First-line and salvage regimens are strictly pharmacologic; no surgical intervention is indicated for uncomplicated *H. pylori* infection.
- •Standard Quadruple Therapy (Bismuth-based, 10–14 days)
- *Itemized Cost (USD, Grade 3A Hospital)*: - Bismuth subcitrate potassium (21-day course): $18–$22 - Tetracycline (14-day course): $6–$9 - Metronidazole (14-day course): $4–$7 - Omeprazole (14-day course): $12–$16 - *Total drug cost*: $40–$54
- •Concomitant Therapy (Non-bismuth quadruple, 10–14 days)
- *Itemized Cost*: - Esomeprazole: $15–$19 - Amoxicillin: $8–$11 - Clarithromycin: $22–$28 - Metronidazole: $4–$7 - *Total drug cost*: $49–$65
- •Diagnostic & Monitoring Fees (Per Episode)
- Stool antigen test (qualitative): $16–$21 - Gastric biopsy + rapid urease test (during endoscopy): $42–$53 - Culture + susceptibility testing (if treatment failure): $68–$85
Surgical/Procedural Options
*No surgical or interventional procedures are indicated for isolated *H. pylori* infection.* Endoscopy is diagnostic only—not therapeutic—and performed solely to assess complications (e.g., ulcer, atrophy, dysplasia). No ablation, resection, or device-based eradication exists for *H. pylori*.
Special/Complex Condition Management
- •Refractory Infection (≥2 failed regimens):
- •Severe Gastroduodenal Ulcer Complication (e.g., bleeding):
- *Note*: This treats the complication—not *H. pylori* itself—but mandates concurrent eradication therapy.
Quick Selection Guide
- •Young adult (<45), no comorbidities, moderate budget: Standard bismuth quadruple ($40–$54) — highest efficacy (>90%), lowest resistance risk.
- •Elderly (>70) or chronic kidney disease: Concomitant therapy ($49–$65) — avoids bismuth accumulation; requires renal dose adjustment of metronidazole.
- •Prior treatment failure + confirmed clarithromycin resistance: Culture-guided regimen ($74–$92) — essential before third-line therapy.
- •Active bleeding ulcer: Urgent endoscopy + hemostasis ($210–$265) + immediate post-procedure quadruple therapy ($40–$54) — dual-pathway management.
- •Low-income patient (<$30 available): Stool antigen test ($16–$21) + empiric bismuth quadruple ($40–$54) — total $56–$75, avoids costly breath testing.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Helicobacter pylori infection Medical Vacation Packages
Curated transparent all-inclusive packages combining Helicobacter pylori infection treatment with China top medical destinations:
